Drug data last refreshed 50m ago · AI intelligence enriched 2w ago
LIBRELEASE is an extended-release oral capsule formulation of chlordiazepoxide, a benzodiazepine approved in 1983. The drug works by enhancing GABAergic neurotransmission in the central nervous system to produce anxiolytic and sedative effects. It is indicated for anxiety disorders and related conditions requiring sustained benzodiazepine therapy.
With LOE approaching and moderate competitive pressure (30%), teams are consolidating around core markets and optimizing existing market position rather than expanding reach.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on LIBRELEASE offers experience managing a mature, stable brand in a regulated therapeutic area with significant compliance and reimbursement complexity. This role emphasizes commercial efficiency, stakeholder management, and defensive strategy—valuable skills for LOE navigation and portfolio diversification within a large pharma environment.
Worked on LIBRELEASE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.